<DOC>
	<DOCNO>NCT00361504</DOCNO>
	<brief_summary>The purpose study evaluate safety profile tapentadol ( CG5503 ) PR dose 100 mg - 250 mg administer twice daily maximum one year period patient least 3-month history low back pain , pain cause knee hip osteoarthritis .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Safety Multiple Doses Tapentadol ( CG5503 ) Prolonged-Release ( PR ) Oxycodone Controlled-Release ( CR ) Patients With Chronic Pain</brief_title>
	<detailed_description>Tapentadol ( CG5503 ) centrally active pain-relieving drug investigate treatment acute chronic pain . This study randomize ( patient assign different treatment base chance ratio 4 patient tapentadol ( CG5503 ) PR every 1 patient oxycodone CR ) , open-label ( Investigator patient know medication allocate ) , active-controlled , parallel-group , multicenter study . It design investigate long-term safety ( side effect one year administration ) effectiveness ( level pain control ) tapentadol ( CG5503 ) PR compare oxycodone CR ( opioid commonly used relief moderate severe pain ) take orally . The study consist screening period ( 14 day ) , washout period ( 3 7 day ) , active treatment phase titration maintenance ( total duration 52 week ) . The dos medication adjust give best therapeutic benefit patient . A total 1123 patient screen . Safety evaluation include monitor adverse event , physical examination , clinical laboratory test . Assessments pain relief include pain intensity numerical rating scale , patient global impression change scale ( PGIC ) . Venous blood sample collect determination serum concentration tapentadol ( CG5503 ) oxycodone . Tapentadol ( CG5503 ) PR also refer Tapentadol ( CG5503 ) Extended Release ( ER ) . Starting oral dose randomly assign tapentadol ( CG5503 ) PR 50 mg oxycodone CR 10 mg twice daily ( BID ) x 3 day ; increase tapentadol ( CG5503 ) 100 mg BID , oxycodone CR 20 mg BID x 4 day ; maintenance phase upward titration may occur minimum 3 day interval increment tapentadol ( CG5503 ) PR 50 mg BID oxycodone CR 10 mg BID . The maximum dos tapentadol ( CG5503 ) PR 250 mg BID oxycodone CR 50 mg BID .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Clinical diagnosis knee hip osteoarthritis history pain reference joint least 3 month clinical diagnosis low back pain benign origin least 3 month Must dissatisfy current analgesic therapy ( e.g . Nonsteroidal antiinflammatory drug NSAIDS , COX2 inhibitor , opioids , paracetamol/acetaminophen Have pain intensity &gt; 4 Numerical Rating Scale Lifelong history seizure disorder epilepsy Any follow within one year : mild/moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm Severe traumatic brain injury within 15 year ( consist one following : brain contusion ( injury result hemorrhage ) , intracranial hematoma , unconsciousness post traumatic amnesia last 24 hour ) residual sequelae suggest transient change consciousness History malignancy within past 2 year , exception successfully treat basal cell carcinoma Presence significant pain associate condition osteoarthritis low back pain could confound assessment selfevaluation pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pain</keyword>
	<keyword>Low Back Pain</keyword>
	<keyword>Hip Pain</keyword>
	<keyword>Knee Pain</keyword>
	<keyword>Backache</keyword>
	<keyword>Tapentadol</keyword>
</DOC>